Caplin Point Laboratories Limited (IN:CAPLIPOINT)
:CAPLIPOINT
CAPLIPOINT Stock Chart & Stats
₹1845.95
-₹76.70(-2.97%)
At close: 4:00 PM EST
₹1845.95
-₹76.70(-2.97%)
Day’s Range― - ―
52-Week Range₹1,502.45 - ₹2,396.95
Previous CloseN/A
Volume128.91K
Average Volume (3M)3.75K
Market Cap
₹126.20B
Enterprise Value₹119.82B
Total Cash (Recent Filing)₹10.17B
Total Debt (Recent Filing)₹85.00M
Price to Earnings (P/E)21.3
Beta1.28
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)21.80
Shares Outstanding76,011,696
10 Day Avg. Volume2,866
30 Day Avg. Volume3,752
Financial Highlights & Ratios
PEG Ratio1.63
Price to Book (P/B)5.30
Price to Sales (P/S)7.78
P/FCF Ratio62.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)100.3
Revenue Forecast (FY)₹26.53B
Bulls Say, Bears Say
Bulls Say
Differentiated Dosage FormsCaplin Point's focus on injectables and ophthalmics creates structural competitive advantages: higher technical barriers, fewer competitors, and stronger pricing power versus commoditized oral solids. These differentiated dosage forms support steadier demand and margin resilience over time.
Revenue Growth And MarginsReported multi-year revenue growth and robust gross/EBITDA/net margins indicate durable operational efficiency and scalable commercial execution. Consistent margin profiles enable reinvestment into registrations and manufacturing capacity, sustaining earnings power across cycles.
Balance Sheet And Cash GenerationStrong operating cash generation and growing free cash flow combined with low leverage provide financial flexibility for capex, regulatory investments, or opportunistic M&A. A robust balance sheet reduces refinancing risk and supports steady long-term strategy execution.
Bears Say
Tender/contract Revenue DependenceSignificant reliance on tender-driven and contract procurement exposes revenue to cyclicality, competitive bid pressure and timing risk. Over months this can compress realized prices, create uneven order flows, and complicate capacity planning for manufacturing and working capital.
Regulatory And Geographic ExposureOperating across regulated and semi-regulated markets raises sustained compliance and approval burdens. Regulatory inspections, differing standards and evolving local rules add recurring capex and operating costs, and create the potential for market access disruption that can persist for months.
Product Registration Timing RiskThe business model depends on securing product registrations then converting them into sales. Regulatory or registration delays create structural pipeline timing risk, delaying revenue recognition after R&D or registration spend and limiting near-term growth visibility.
Caplin Point Laboratories Limited News
CAPLIPOINT FAQ
What was Caplin Point Laboratories Limited’s price range in the past 12 months?
Caplin Point Laboratories Limited lowest stock price was ₹1502.45 and its highest was ₹2396.95 in the past 12 months.
What is Caplin Point Laboratories Limited’s market cap?
Caplin Point Laboratories Limited’s market cap is ₹126.20B.
When is Caplin Point Laboratories Limited’s upcoming earnings report date?
Caplin Point Laboratories Limited’s upcoming earnings report date is May 14, 2026 which is in 35 days.
How were Caplin Point Laboratories Limited’s earnings last quarter?
Caplin Point Laboratories Limited released its earnings results on Feb 05, 2026. The company reported ₹21.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹21.8.
Is Caplin Point Laboratories Limited overvalued?
According to Wall Street analysts Caplin Point Laboratories Limited’s price is currently Overvalued.
Does Caplin Point Laboratories Limited pay dividends?
Caplin Point Laboratories Limited pays a Quarterly dividend of ₹3 which represents an annual dividend yield of 0.31%. See more information on Caplin Point Laboratories Limited dividends here
What is Caplin Point Laboratories Limited’s EPS estimate?
Caplin Point Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caplin Point Laboratories Limited have?
Caplin Point Laboratories Limited has 76,011,696 shares outstanding.
What happened to Caplin Point Laboratories Limited’s price movement after its last earnings report?
Caplin Point Laboratories Limited reported an EPS of ₹21.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.419%.
Which hedge fund is a major shareholder of Caplin Point Laboratories Limited?
Currently, no hedge funds are holding shares in IN:CAPLIPOINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
―
Granules India Limited
―
NATCO Pharma Limited
―
Neuland Laboratories Ltd.
―